- Home
- IGA vs ACRS Comparison
IGA vs ACRS Comparison
Compare IGA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- ACRS
- Stock Information
- Founded
- IGA 2005
- ACRS 2012
- Country
- IGA United States
- ACRS United States
- Employees
- IGA N/A
- ACRS N/A
- Industry
- IGA Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- IGA Finance
- ACRS Health Care
- Exchange
- IGA Nasdaq
- ACRS Nasdaq
- Market Cap
- IGA 147.6M
- ACRS 132.0M
- IPO Year
- IGA N/A
- ACRS 2015
- Fundamental
- Price
- IGA $9.55
- ACRS $1.58
- Analyst Decision
- IGA
- ACRS Strong Buy
- Analyst Count
- IGA 0
- ACRS 6
- Target Price
- IGA N/A
- ACRS $11.67
- AVG Volume (30 Days)
- IGA 42.3K
- ACRS 747.7K
- Earning Date
- IGA 01-01-0001
- ACRS 05-06-2025
- Dividend Yield
- IGA 8.93%
- ACRS N/A
- EPS Growth
- IGA N/A
- ACRS N/A
- EPS
- IGA N/A
- ACRS N/A
- Revenue
- IGA N/A
- ACRS $18,720,000.00
- Revenue This Year
- IGA N/A
- ACRS N/A
- Revenue Next Year
- IGA N/A
- ACRS N/A
- P/E Ratio
- IGA N/A
- ACRS N/A
- Revenue Growth
- IGA N/A
- ACRS N/A
- 52 Week Low
- IGA $7.77
- ACRS $0.95
- 52 Week High
- IGA $8.88
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- IGA 49.65
- ACRS 27.27
- Support Level
- IGA $9.54
- ACRS $1.75
- Resistance Level
- IGA $9.68
- ACRS $2.03
- Average True Range (ATR)
- IGA 0.11
- ACRS 0.15
- MACD
- IGA -0.02
- ACRS -0.03
- Stochastic Oscillator
- IGA 20.00
- ACRS 13.77
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.